Project

A targeted nanomedicine strategy for in vivo CD8+ T cell engineering

Code
01D03021
Duration
01 October 2021 → 31 October 2022
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Medical and health sciences
    • Applied immunology
    • Biopharmaceuticals
    • Pharmaceutical technology
  • Engineering and technology
    • Nanomaterials
Keywords
immunotherapy T cells cancer nanotechnology
 
Project description

The goal of this project is to investigate a strategy to target CD8+ T cells in vivo  for subsequent cellspecific
delivery of nanoparticle-formulated therapeutics. Via this technology, we aim to modulate T cells in vivo in the blood and in the tumor microenvironment.